HK1199837A1 - Humanized antibodies to inkt - Google Patents
Humanized antibodies to inkt Download PDFInfo
- Publication number
- HK1199837A1 HK1199837A1 HK15100381.0A HK15100381A HK1199837A1 HK 1199837 A1 HK1199837 A1 HK 1199837A1 HK 15100381 A HK15100381 A HK 15100381A HK 1199837 A1 HK1199837 A1 HK 1199837A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inkt
- humanized antibodies
- suppress
- subject
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552337P | 2011-10-27 | 2011-10-27 | |
| US201161552337P | 2011-10-27 | ||
| PCT/US2012/062124 WO2013063395A1 (en) | 2011-10-27 | 2012-10-26 | Humanized antibodies to inkt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1199837A1 true HK1199837A1 (en) | 2015-07-24 |
Family
ID=48168549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15100381.0A HK1199837A1 (en) | 2011-10-27 | 2012-10-26 | Humanized antibodies to inkt |
| HK14113013.0A HK1199405A1 (en) | 2011-10-27 | 2012-10-26 | Humanized antibodies to inkt |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14113013.0A HK1199405A1 (en) | 2011-10-27 | 2012-10-26 | Humanized antibodies to inkt |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9932402B2 (https=) |
| EP (1) | EP2755688A4 (https=) |
| JP (1) | JP2015502340A (https=) |
| KR (1) | KR20140093964A (https=) |
| CN (1) | CN103945867B (https=) |
| AU (1) | AU2012328588C1 (https=) |
| BR (1) | BR112014009962A2 (https=) |
| CA (1) | CA2853719A1 (https=) |
| HK (2) | HK1199837A1 (https=) |
| IL (1) | IL232017A0 (https=) |
| RU (1) | RU2014120694A (https=) |
| SG (1) | SG11201401319XA (https=) |
| WO (1) | WO2013063395A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970451A1 (en) * | 2013-03-14 | 2016-01-20 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
| WO2015069697A2 (en) * | 2013-11-05 | 2015-05-14 | Nkt Therapeutics Inc. | Combination therapy |
| ES2866935T3 (es) * | 2014-01-10 | 2021-10-20 | Anaptysbio Inc | Anticuerpos dirigidos contra interleucina-33 (IL-33) |
| US20170182077A1 (en) * | 2014-02-14 | 2017-06-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| WO2016013672A1 (ja) * | 2014-07-25 | 2016-01-28 | 国立研究開発法人理化学研究所 | メモリーインバリアントｎｋｔ細胞マーカー |
| US20160022777A1 (en) * | 2014-07-28 | 2016-01-28 | Nkt Therapeutics Inc. | Combination therapy with il-12 |
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| JP7003036B2 (ja) | 2015-12-02 | 2022-02-04 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
| CN109071636A (zh) | 2016-03-29 | 2018-12-21 | 斯特库比股份有限公司 | 用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法 |
| EP3452510A4 (en) | 2016-04-04 | 2020-01-15 | Bioverativ USA Inc. | ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF |
| CN109715666B (zh) | 2016-07-20 | 2023-02-21 | 斯特库比股份有限公司 | 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法 |
| CA3037144A1 (en) * | 2016-09-16 | 2018-03-22 | Shanghai Henlius Biotech, Inc. | Anti-pd-1 antibodies |
| WO2020156335A1 (zh) * | 2019-01-29 | 2020-08-06 | 上海交通大学 | 一种嵌合抗原受体及其应用 |
| EP4139350A4 (en) | 2020-04-20 | 2024-04-24 | Genzyme Corporation | Humanized anti-complement factor bb antibodies and uses thereof |
| JP2023522979A (ja) * | 2020-04-23 | 2023-06-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｉＮＫＴ細胞の活性化による老化細胞の排除 |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| WO1997016203A1 (en) | 1995-11-01 | 1997-05-09 | Genetics Institute, Inc. | Methods for administration of il-12 |
| AU2087799A (en) | 1997-12-31 | 1999-07-19 | Brigham And Women's Hospital | Diagnostic and therapeutic methods based upon valpha24jalphaq t cells |
| JP5184732B2 (ja) | 2000-06-19 | 2013-04-17 | ベス イスラエル デアコネス メディカル センター | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 |
| WO2003007889A2 (en) * | 2001-07-17 | 2003-01-30 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| ES2365210T3 (es) | 2002-06-14 | 2011-09-26 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health | Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales. |
| US9809654B2 (en) * | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1784196B1 (en) | 2004-08-27 | 2016-12-21 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
| WO2006060117A2 (en) * | 2004-11-02 | 2006-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for inhibition of nkt cells |
| PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| WO2008140487A2 (en) * | 2006-11-14 | 2008-11-20 | Elusys Therapeutics, Inc. | Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use |
| WO2008100912A1 (en) | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
| US8012484B2 (en) | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
| US20090028849A1 (en) | 2007-07-24 | 2009-01-29 | O'brien Rebecca L | Agents and methods for inhibition of airway hyperresponsiveness |
| US20110300154A1 (en) * | 2007-08-21 | 2011-12-08 | Children's Medical Center Corporation | Treatment of airway hyperreactivity |
| EP2586797A3 (en) * | 2007-11-27 | 2013-07-24 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| GB0902916D0 (en) * | 2009-02-20 | 2009-04-08 | Fusion Antibodies Ltd | Antibody therapy |
| WO2011112889A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY |
| WO2011149881A2 (en) | 2010-05-24 | 2011-12-01 | Children's Medical Center Corporation | Methods for the treatment and prevention of inflammatory diseases |
| PT2785683T (pt) | 2011-11-30 | 2020-04-16 | Ludwig Inst For Cancer Res Ltd | Moduladores de célula inkt e métodos para o seu uso |
| WO2015069697A2 (en) | 2013-11-05 | 2015-05-14 | Nkt Therapeutics Inc. | Combination therapy |
| US20160022777A1 (en) | 2014-07-28 | 2016-01-28 | Nkt Therapeutics Inc. | Combination therapy with il-12 |
-
2012
- 2012-10-26 JP JP2014539044A patent/JP2015502340A/ja active Pending
- 2012-10-26 CN CN201280053174.3A patent/CN103945867B/zh not_active Expired - Fee Related
- 2012-10-26 BR BR112014009962A patent/BR112014009962A2/pt not_active IP Right Cessation
- 2012-10-26 WO PCT/US2012/062124 patent/WO2013063395A1/en not_active Ceased
- 2012-10-26 HK HK15100381.0A patent/HK1199837A1/xx unknown
- 2012-10-26 AU AU2012328588A patent/AU2012328588C1/en not_active Ceased
- 2012-10-26 CA CA2853719A patent/CA2853719A1/en not_active Abandoned
- 2012-10-26 US US13/661,386 patent/US9932402B2/en not_active Expired - Fee Related
- 2012-10-26 EP EP12843689.6A patent/EP2755688A4/en not_active Withdrawn
- 2012-10-26 SG SG11201401319XA patent/SG11201401319XA/en unknown
- 2012-10-26 HK HK14113013.0A patent/HK1199405A1/xx unknown
- 2012-10-26 KR KR1020147014125A patent/KR20140093964A/ko not_active Abandoned
- 2012-10-26 RU RU2014120694/10A patent/RU2014120694A/ru not_active Application Discontinuation
-
2014
- 2014-04-08 IL IL232017A patent/IL232017A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014120694A (ru) | 2015-12-10 |
| US9932402B2 (en) | 2018-04-03 |
| CA2853719A1 (en) | 2013-05-02 |
| JP2015502340A (ja) | 2015-01-22 |
| US20130136735A1 (en) | 2013-05-30 |
| EP2755688A4 (en) | 2014-08-06 |
| WO2013063395A1 (en) | 2013-05-02 |
| HK1199405A1 (en) | 2015-07-03 |
| KR20140093964A (ko) | 2014-07-29 |
| EP2755688A1 (en) | 2014-07-23 |
| CN103945867B (zh) | 2018-01-02 |
| AU2012328588B2 (en) | 2015-07-09 |
| BR112014009962A2 (pt) | 2019-09-24 |
| AU2012328588C1 (en) | 2015-12-03 |
| IL232017A0 (en) | 2014-05-28 |
| AU2012328588A1 (en) | 2014-04-24 |
| CN103945867A (zh) | 2014-07-23 |
| SG11201401319XA (en) | 2014-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1199837A1 (en) | Humanized antibodies to inkt | |
| WO2013064701A3 (en) | Specific antibodies and their isolation with anti-idiotypic antibodies | |
| WO2013006490A3 (en) | Antibodies that specifically bind to tim3 | |
| WO2014011988A3 (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| WO2010129917A3 (en) | Anti-cd100 antibodies and methods for using the same | |
| WO2009014708A3 (en) | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | |
| PH12014501108A1 (en) | Anti-il-36r antibodies | |
| WO2013063613A3 (en) | Methods and compositions related to intracellular neutralization by igg | |
| WO2012031099A3 (en) | Anti-cxcl13 antibodies and methods of using the same | |
| WO2015054691A3 (en) | Tem8 antibodies and their use | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
| WO2011123489A3 (en) | Anti-cd40 antibodies | |
| WO2013152001A3 (en) | Anti-hla-b*27 antibodies and uses thereof | |
| WO2012162067A3 (en) | Cd3-binding molecules capable of binding to human and non-human cd3 | |
| AU2012335543A8 (en) | HER3 antibodies and uses thereof | |
| EP4371570A3 (en) | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b | |
| HK1207654A1 (en) | Modified antibody regions and uses thereof | |
| MX341958B (es) | Anticuerpos contra el il33r humano y usos de los mismos. | |
| EP2672979A2 (en) | Anti cd4 antibodies to prevent in particular graft-versus-host-disease (gvhd) | |
| AU2012323781A8 (en) | Antibodies to CD1d | |
| WO2013149111A3 (en) | Anti-tlr4 antibodies and uses thereof | |
| WO2013006449A3 (en) | Anti-properdin antibodies and uses thereof | |
| HK1201855A1 (en) | Antibodies and methods of treating cancer |